Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial

Bookmark and Share
Published: 1 Jun 2015
Views: 5407
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Prof Gnant talks to ecancertv at ASCO 2015 about the use of adjuvant denosumab to reduce bone problems in postmenopausal women with breast cancer receiving treatment with aromatase inhibitors.

Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopaenia, osteoporosis, and fractures - but the addition of adjuvant denosumab to the treatment plan reduces patients' risk of clinical fractures.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.